Ladenburg Thalmann Upgrades Forte Biosciences to Buy, Announces $2.75 Price Target
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Michael Higgins upgrades Forte Biosciences (FBRX) from Neutral to Buy and sets a price target of $2.75.

April 08, 2024 | 9:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Forte Biosciences was upgraded from Neutral to Buy by Ladenburg Thalmann, with a new price target of $2.75.
Upgrades by analysts, especially from Neutral to Buy, typically signal a positive outlook on the stock, suggesting potential upside. The new price target of $2.75 indicates a specific expectation for stock price increase, which can influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100